---
schema_version: "secwatch.filing_event.v1"
accession: "0001387131-23-006742"
form_type: "8-K"
ticker: null
cik: "0000887247"
company_name: "DMK PHARMACEUTICALS Corp"
filed_at: "2023-05-22T23:59:59+00:00"
generated_at: "2026-06-14T18:57:53.751591+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adamis Pharmaceuticals effects 1-for-70 reverse stock split to regain Nasdaq compliance

## Summary
- Reverse split effective 12:01 a.m. ET on May 22, 2023; shares begin trading split-adjusted same day.
- Ratio of 1-for-70 approved by board after shareholders authorized range of 1-for-2 to 1-for-100.
- Purpose: increase stock price to meet Nasdaq minimum $1.00 bid for 10 consecutive days by June 26, 2023.
- Split also a closing condition of the previously announced merger with DMK Pharmaceuticals.
- No change to authorized shares (200M common); CUSIP changes to 00547W 307; symbol remains ADMP.

## SEC filing metadata
- accession: 0001387131-23-006742
- form_type: 8-K
- cik: 0000887247
- company_name: DMK PHARMACEUTICALS Corp
- filed_at: 2023-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887247/000138713123006742/0001387131-23-006742-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887247/000138713123006742/admp-8k_052223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001387131-23-006742
- JSON: https://secwatch.observer/filing/0001387131-23-006742.json
- Plain text: https://secwatch.observer/filing/0001387131-23-006742.txt

## Key facts
- Governance Changes
  DMK PHARMACEUTICALS Corp: The company filed a Certificate of Amendment to its Restated Certificate of Incorporation to effect a 1-for-70 reverse stock split of its common stock, effective 12:01 a.m. Eastern time (effective 2023-05-22).
  - Change: charter amendment
  - Effective: 2023-05-22
  source text: Adamis Pharmaceuticals Corporation (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of Delaware, effective 12:01 a.m. Eastern time, to effect a 1-for-70 reverse stock split of the outstanding shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) (the “Reverse Stock Split”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123006742/0001387131-23-006742-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.